Demant A/S (OTCMKTS:WILYY – Get Rating) and Bone Biologics (OTC:BBLG – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Volatility and Risk
Demant A/S has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Get
Demant A/S alerts:
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Demant A/S and Bone Biologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Demant A/S | 4 | 0 | 1 | 0 | 1.40 |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Bone Biologics has a consensus price target of $2.25, suggesting a potential upside of 650.00%. Given Bone Biologics' stronger consensus rating and higher possible upside, analysts plainly believe Bone Biologics is more favorable than Demant A/S.
Insider & Institutional Ownership
7.6% of Bone Biologics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Demant A/S and Bone Biologics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Demant A/S | N/A | N/A | N/A |
| Bone Biologics | N/A | 7,587.33% | 7,258.20% |
Earnings and Valuation
This table compares Demant A/S and Bone Biologics' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Demant A/S | $2.93 billion | 2.26 | $399.82 million | N/A | N/A |
| Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
Demant A/S has higher revenue and earnings than Bone Biologics.
Summary
Bone Biologics beats Demant A/S on 5 of the 8 factors compared between the two stocks.
About Demant A/S
(Get Rating)
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Demant A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demant A/S and related companies with MarketBeat.com's FREE daily email newsletter.
